- Home
- KZIA vs DOMH Comparison
KZIA vs DOMH Comparison
Compare KZIA & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- DOMH
- Stock Information
- Founded
- KZIA 1994
- DOMH 1967
- Country
- KZIA Australia
- DOMH United States
- Employees
- KZIA N/A
- DOMH N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- DOMH Health Care
- Exchange
- KZIA Nasdaq
- DOMH Nasdaq
- Market Cap
- KZIA 5.1M
- DOMH 83.3M
- IPO Year
- KZIA 1999
- DOMH N/A
- Fundamental
- Price
- KZIA $10.45
- DOMH $4.95
- Analyst Decision
- KZIA Strong Buy
- DOMH
- Analyst Count
- KZIA 2
- DOMH 0
- Target Price
- KZIA $14.00
- DOMH N/A
- AVG Volume (30 Days)
- KZIA 745.7K
- DOMH 276.9K
- Earning Date
- KZIA 07-22-2025
- DOMH 08-07-2025
- Dividend Yield
- KZIA N/A
- DOMH 6.41%
- EPS Growth
- KZIA N/A
- DOMH N/A
- EPS
- KZIA N/A
- DOMH N/A
- Revenue
- KZIA $1,549,158.00
- DOMH $24,891,000.00
- Revenue This Year
- KZIA N/A
- DOMH N/A
- Revenue Next Year
- KZIA N/A
- DOMH N/A
- P/E Ratio
- KZIA N/A
- DOMH N/A
- Revenue Growth
- KZIA 248983.08
- DOMH 630.80
- 52 Week Low
- KZIA $2.86
- DOMH $0.83
- 52 Week High
- KZIA $79.00
- DOMH $13.58
- Technical
- Relative Strength Index (RSI)
- KZIA 72.75
- DOMH 44.76
- Support Level
- KZIA $5.86
- DOMH $4.94
- Resistance Level
- KZIA $7.20
- DOMH $5.21
- Average True Range (ATR)
- KZIA 1.17
- DOMH 0.40
- MACD
- KZIA 0.15
- DOMH -0.08
- Stochastic Oscillator
- KZIA 82.21
- DOMH 0.64
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.